Goserelin Acetate

CHEMBL1200501 Phase 4 Approved Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1329.5 g/mol

LogP

—

Phase

4

The acetate salt form of goserelin, a gonadotropin-releasing hormone agonist delivered as a subcutaneous implant to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, and benign prostatic hyperplasia. After an initial flare in hormone levels, it produces sustained suppression beneficial in hormone-sensitive conditions. This is the commercially available formulation used in clinical practice.

Molecular Weight

1329.5000 g/mol

TPSA

533.00 Å²

Therapeutic Areas

Bladder Cancer Breast Cancer Colorectal Cancer Endometriosis Hypertension Lymphoma Major Depressive Disorder Melanoma Non-Small Cell Lung Cancer Osteoporosis Ovarian Cancer Pancreatic Cancer Prostate Cancer Schizophrenia Thyroid Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O

InChI

InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1

Molecular Formula

C61H88N18O16

HBD / HBA

18 / 18

Rotatable Bonds

32

Heavy Atoms

95

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The acetate salt form of goserelin, a gonadotropin-releasing hormone agonist delivered as a subcutaneous implant to suppress sex hormone production in conditions such as prostate cancer, breast cancer, endometriosis, and benign prostatic hyperplasia. After an initial flare in hormone levels, it produces sustained suppression beneficial in hormone-sensitive conditions. This is the commercially available formulation used in clinical practice.

Yes, Goserelin Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200501. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16052011. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Goserelin Acetate on PillFYI

Structure

Quick Data

Formula: C61H88N18O16
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.